These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 15852222)

  • 1. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
    Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
    Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel.
    Tantry US; Bliden KP; Gurbel PA
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1627-33. PubMed ID: 17107286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
    Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.
    Sugidachi A; Asai F; Yoneda K; Iwamura R; Ogawa T; Otsuguro K; Koike H
    Br J Pharmacol; 2001 Jan; 132(1):47-54. PubMed ID: 11156560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
    Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
    J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Postgrad Med J; 2006 Jun; 82(968):404-10. PubMed ID: 16754711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
    Dobesh PP
    Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
    Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
    Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
    Dovlatova NL; Jakubowski JA; Sugidachi A; Heptinstall S
    J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedside evaluation of thienopyridine antiplatelet therapy.
    Price MJ
    Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
    [No Abstract]   [Full Text] [Related]  

  • 19. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
    Jakubowski JA; Matsushima N; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Br J Clin Pharmacol; 2007 Apr; 63(4):421-30. PubMed ID: 17076696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
    Small DS; Payne CD; Kothare P; Yuen E; Natanegara F; Teng Loh M; Jakubowski JA; Richard Lachno D; Li YG; Winters KJ; Farid NA; Ni L; Salazar DE; Tomlin M; Kelly R
    Clin Ther; 2010 Feb; 32(2):365-79. PubMed ID: 20206794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.